Brian Kelly

Brian Kelly, PhD, DABCC, FADLM

Languages spoken: English

Academic Information

Departments Adjunct - Pathology

Board Certification

  • American Board of Clinical Chemistry

Brian N. Kelly, PhD, DABCC, FADLM, After earning undergraduate degrees in Biochemistry and Molecular, Cellular, and Developmental Biology from the University of Colorado I pursued a PhD in Biochemistry from the University of Utah. Subsequently, I completed a 3-year post-doctoral fellowship in Clinical Chemistry and Laboratory Medicine at the University of Virginia. As a clinical toxicology specialist with ARUP, I review test results to investigate whether a patient is compliant with prescribed medications and not using illicit or non-prescribed medications. At ARUP, I also have the pleasure of teaching residents and fellows in Pathology. In my independent consulting business, I assist small to mid-size clinical laboratories in the implementation of liquid-chromatography mass-spectrometry based analysis of biological specimens, among other methods, as well as providing ongoing regulatory oversight.

Education History

Research Fellow Sports Medicine Research and Testing Laboratory
 Research Fellow
Fellowship University of Virginia
 Clinical Research Fellow
Doctoral Training University of Utah
 PhD
Undergraduate University of Colorado
 BA
Undergraduate University of Colorado
 BA

Selected Publications

Journal Article

  1. Boyd JM, Kelly BN, McMillin GA (2024). Prevalence of Gabapentinoid and Opioid Copositives in a Reference Laboratory Patient Population. J Appl Lab Med, 9(4), 861-863. (Read full article)
  2. Kelly BN (2023). UTI detection by PCR: Improving patient outcomes. J Mass Spectrom Adv Clin Lab, 28, 60-62. (Read full article)
  3. McMillin GA, Johnson-Davis KL, Kelly BN, Scott B, Yang YK (2020). Impact of the Opioid Epidemic on Drug Testing. Ther Drug Monit, 43(1), 14-24. (Read full article)
  4. Snozek CLH, Baskin LB, Boyd JM, Kelly BN, Krasowski MD, Sadrzadeh SMH, Tacker DH (2020). How Can Routine Clinical Laboratories Keep Up with the Opioid Crisis? Clin Chem, 67(2), 338-344. (Read full article)
  5. Yang YK, Johnson-Davis KL, Kelly BN, McMillin GA (2020). Demand for Interpretation of a Urine Drug Testing Panel Reflects the Changing Landscape of Clinical Needs; Opportunities for the Laboratory to Provide Added Clinical Value. J Appl Lab Med, 5(5), 858-868. (Read full article)
  6. Kelly BN, Haverstick DM, Lee JK, Thorner MO, Vance ML, Xin W, Bruns DE (2014). Circulating microRNA as a biomarker of human growth hormone administration to patients. Drug Test Anal, 6(3), 234-8. (Read full article)
  7. Kelly BN, Madsen M, Sharpe K, Nair V, Eichner D (2013). A population study of urine glycerol concentrations in elite athletes competing in North America. Drug Test Anal, 5(11-12), 890-5. (Read full article)
  8. Kelly BN, Haverstick DM, Vance ML, Thorner MO, Bruns DE (2012). Quantification of growth hormone mRNA in blood. Clin Chim Acta, 414, 206-10. (Read full article)
  9. Pornillos O, Ganser-Pornillos BK, Kelly BN, Hua Y, Whitby FG, Stout CD, Sundquist WI, Hill CP, Yeager M (2009). X-ray structures of the hexameric building block of the HIV capsid. Cell, 137(7), 1282-92. (Read full article)
  10. Kelly BN, Kyere S, Kinde I, Tang C, Howard BR, Robinson H, Sundquist WI, Summers MF, Hill CP (2007). Structure of the antiviral assembly inhibitor CAP-1 complex with the HIV-1 CA protein. J Mol Biol, 373(2), 355-66. (Read full article)
  11. Kelly BN, Howard BR, Wang H, Robinson H, Sundquist WI, Hill CP (2006). Implications for viral capsid assembly from crystal structures of HIV-1 Gag(1-278) and CA(N)(133-278). Biochemistry, 45(38), 11257-66. (Read full article)
  12. Sundquist WI, Schubert HL, Kelly BN, Hill GC, Holton JM, Hill CP (2004). Ubiquitin recognition by the human TSG101 protein. Mol Cell, 13(6), 783-9. (Read full article)

Commentary

  1. Brian N Kelly, PhD (Fall 2017). Sports Drug Testing Update.

Case Report

  1. Kelly, BN, Silverman, LM, Bruns, DE (2013). Unexpected Serum Protein Electrophoresis Results: Finding the lost monoclonal protein.

Letter

  1. Kelly BN, Haverstick DM, Bruns DE (2012). Interference in a glucose dehydrogenase-based glucose meter revisited. [Letter to the editor]. Clin Chim Acta, 413(7-8), 829-30. (Read full article)
  2. Kelly BN, Haverstick DM, Bruns DE (2010). Interference in a glucose dehydrogenase-based glucose meter. [Letter to the editor]. Clin Chem, 56(6), 1038-40. (Read full article)

Video/Film/CD/Web/Podcast

  1. Brian N Kelly (2009). One Cyclist’s Experience [Web]. Anti-Doping Research Web Site.

Patent

  1. Bruns DE, Haverstick DM, Kelly B (2019). Compositions and Methods for Detecting Aberrant Regulation, Expression, and Levels of hGH. U.S. Patent No. US 14/035,422. Washington, D.C.:U.S. Patent and Trademark Office.